US FDA approves Pfizer's RSV vaccine

The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc.

Published - June 01, 2023 04:10 am IST

The USFDA approved Pfizer Inc’s respiratory syncytial virus vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.

The USFDA approved Pfizer Inc’s respiratory syncytial virus vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. | Photo Credit: Reuters

The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.

The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc. Pfizer's vaccine was approved for people aged 60 and older, the company said, the same age group as GSK's shot.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.